Provided by Tiger Fintech (Singapore) Pte. Ltd.

Madrigal Pharmaceuticals

348.35
+25.337.84%
Post-market: 348.350.00000.00%19:49 EDT
Volume:382.11K
Turnover:130.08M
Market Cap:7.69B
PE:-15.91
High:348.35
Open:328.50
Low:326.70
Close:323.02
Loading ...

Q4 2024 Madrigal Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
27 Feb

JMP Securities Reaffirms Their Buy Rating on Madrigal Pharmaceuticals (MDGL)

TIPRANKS
·
27 Feb

Madrigal Pharmaceuticals Shares Jump After Q4 Beat, Release of New Data on Steatohepatitis Drug

MT Newswires Live
·
27 Feb

Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Zacks
·
27 Feb

Madrigal Pharmaceuticals Phase 3 data ‘encouraging,’ says UBS

TIPRANKS
·
27 Feb

BUZZ-Madrigal rises on robust sales and long-term data for liver disease drug

Reuters
·
26 Feb

Why Madrigal Pharmaceuticals Stock Is Soaring Today

Motley Fool
·
26 Feb

Stock Track | Madrigal Pharmaceuticals Soars 8.24% in Pre-market on Promising Rezdiffra Data and Better-Than-Expected Q4 Results

Stock Track
·
26 Feb

Madrigal Pharmaceuticals Shares up 11.9% After Q4 Sales of Co's Fatty Liver Disease Drug Beat Estimates

THOMSON REUTERS
·
26 Feb

Madrigal Pharmaceuticals Says Steatohepatitis Drug Shows 'Marked Reductions' in Patients' Liver Stiffness

MT Newswires Live
·
26 Feb

Madrigal Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
26 Feb

Sector Update: Health Care Stocks Decline Pre-Bell Wednesday

MT Newswires Live
·
26 Feb

Stock Track | Madrigal Pharmaceuticals Soars 6.63% Pre-Market on Positive Q4 Results and Promising Rezdiffra Data

Stock Track
·
26 Feb

Madrigal (MDGL) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
26 Feb

BRIEF-Madrigal Announces Two-Year Data From The Compensated Mash Cirrhosis Arm Of The Maestro-Nafld-1 Trial

Reuters
·
26 Feb

Madrigal Pharmaceuticals' Q4 Net Loss Narrows, Revenue Tops Estimates

MT Newswires Live
·
26 Feb